Serina Therapeutics (SER) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SER SEC filings page.
Serina Therapeutics (SER) reported $130K in revenue for fiscal year 2025, up 132.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage spending dominates Serina’s model: operating cash use is funded largely by financing while equity has been compressed toward zero.
In FY2025, research and development rose to$13.2M while revenue was only$130K , indicating that reported activity remains small relative to the company’s scientific investment. Operating cash flow of-$18.0M was nearly identical to free cash flow of-$18.0M , showing that cash consumption came chiefly from ongoing operations rather than heavy capital spending.
External financing is carrying the operating model: financing provided
Balance-sheet flexibility has narrowed: FY2025 liabilities were
Financial Health Signals
Serina Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Serina Therapeutics scores -18.29, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($63.5M) relative to total liabilities ($7.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Serina Therapeutics passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Serina Therapeutics reported a net loss of $19.2M while operations used $18.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Serina Therapeutics reported an operating loss of $24.0M against $213K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Serina Therapeutics generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Serina Therapeutics reported -$6.4M in net income in Q2 2026. This represents an increase of 1.4% from the same quarter a year earlier. Against the prior quarter it is up 7.9%.
Serina Therapeutics earned -$0.55 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 5.2%.
Not reported for Q2 2026.
Cash & Balance Sheet
Serina Therapeutics recorded an outflow of $6.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 76.8% from the same quarter a year earlier. Against the prior quarter it is down 46.1%.
Serina Therapeutics held $23.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Serina Therapeutics's ROE was -33.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 323.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Serina Therapeutics invested $3.8M in research and development in Q2 2026. This represents an increase of 21.1% from the same quarter a year earlier. Against the prior quarter it is up 19.3%.
Serina Therapeutics invested $28K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 39.1% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.
Not reported for Q2 2026.
SER Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | N/A | N/A | $0-100.0% | $130K+154.9% | $0-100.0% | N/A | $14K-51.7% |
| R&D Expenses | $3.8M+21.1% | $3.2M+8.4% | N/A | $3.7M+51.2% | $3.2M+97.7% | $3.0M+166.8% | N/A | $2.4M+300.5% |
| SG&A Expenses | $3.0M+16.7% | $3.1M+6.0% | N/A | $2.7M-5.8% | $2.5M+9.5% | $2.9M+138.3% | N/A | $2.9M+227.4% |
| Operating Income | -$6.8M-21.9% | N/A | N/A | -$6.4M-20.3% | -$5.6M-43.9% | -$5.9M-152.4% | N/A | -$5.3M-263.1% |
| EBITDA | N/A | N/A | N/A | -$6.4M-20.3% | -$5.6M-45.2% | -$5.9M-155.1% | N/A | -$5.3M-277.0% |
| Interest Expense | $203K+2155.6% | $189K | N/A | $6K-62.5% | $9K-97.1% | $0-100.0% | N/A | $16K-99.5% |
| Income Tax | N/A | $7K | N/A | N/A | N/A | $0 | N/A | N/A |
| Net Income | -$6.4M+1.4% | -$6.9M-43.3% | N/A | -$4.6M-425.2% | -$6.4M-223.9% | -$4.8M+67.9% | N/A | $1.4M-19.5% |
| EPS (Basic) | -$0.55+16.7% | -$0.58-18.4% | -$0.31-14.8% | -$0.45-381.3% | -$0.66-208.2% | -$0.49+90.9% | -$0.27+98.0% | $0.16-80.0% |
| EPS (Diluted) | -$0.55 | -$0.58-18.4% | -$0.31-14.8% | -$0.45-446.2% | -$0.66-229.4% | -$0.49 | -$0.27 | $0.13 |
| Diluted Shares (Avg) | 16M | 12M+23.5% | N/A | 10M-3.8% | 10M-1.5% | 10M | N/A | 11M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
SER Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $25.8M+188.7% | $27.3M+305.6% | $7.0M+3.4% | $12.4M+67.0% | $8.9M-16.5% | $6.7M-38.0% | $6.7M-25.0% | $7.4M-39.1% |
| Current Assets | $25.0M+213.2% | $26.5M+360.1% | $6.1M+7.1% | $11.5M+112.0% | $8.0M-10.4% | $5.8M-35.6% | $5.7M-25.5% | $5.4M+375.3% |
| Cash & Equivalents | $23.0M+281.1% | $24.5M+474.8% | $3.1M-16.8% | $8.6M+170.6% | $6.0M-0.4% | $4.3M-51.0% | $3.7M-51.8% | $3.2M+702.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $7.1M-2.9% | $9.7M+87.0% | $7.0M+12.4% | $10.8M-49.1% | $7.3M-73.1% | $5.2M-65.9% | $6.2M-84.9% | $21.3M-46.5% |
| Current Liabilities | $3.8M+5.6% | $6.3M+169.6% | $3.6M+50.6% | $8.8M-35.0% | $3.6M-71.8% | $2.4M-83.3% | $2.4M+67.4% | $13.5M+321.8% |
| Non-Current Liabilities | $3.3M-11.0% | $3.3M+18.1% | $3.4M-11.0% | $2.0M-73.8% | $3.7M-74.2% | $2.8M+155.0% | $3.9M-90.3% | $7.7M-78.8% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $11.2M |
| Total Equity | $18.7M+939.4% | $17.6M+936.3% | -$37K-105.8% | $1.8M+112.8% | $1.8M+111.0% | $1.7M+139.5% | $641K+102.0% | -$13.8M+50.0% |
| Retained Earnings | -$76.8M-38.1% | -$70.4M-43.3% | -$63.5M-43.3% | -$60.2M-44.7% | -$55.6M-29.3% | -$49.1M-1.9% | -$44.3M-33.6% | -$41.6M+67.4% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
SER Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.7M-78.2% | -$4.6M-5.7% | -$6.0M-31.5% | -$3.9M-30.0% | -$3.8M+53.2% | -$4.3M-174.1% | -$4.6M-3892.6% | -$3.0M-189.3% |
| Depreciation & Amortization | N/A | $0 | N/A | $0 | $0-100.0% | $0-100.0% | N/A | $0-100.0% |
| Stock-Based Compensation | $1.1M+18.1% | $1.1M+12.7% | N/A | $999K-8.9% | $890K+94.3% | $956K+1703.8% | N/A | $1.1M |
| Capital Expenditures | $28K-39.1% | $25K | $0-100.0% | $13K+333.3% | $46K | $0-100.0% | $5K-92.9% | $3K-97.5% |
| Free Cash Flow | -$6.7M-76.8% | -$4.6M-6.3% | -$6.0M-31.3% | -$3.9M-30.3% | -$3.8M+52.6% | -$4.3M-171.7% | -$4.6M-9107.8% | -$3.0M-159.4% |
| Investing Cash Flow | -$28K+39.1% | -$25K | $0+100.0% | -$13K-333.3% | -$46K | $0+100.0% | -$5K+92.9% | -$3K+97.5% |
| Financing Cash Flow | $5.2M-6.6% | $26.1M+429.9% | $481K-90.4% | $6.4M+7393.0% | $5.6M+3.8% | $4.9M+80.2% | $5.0M+38800.0% | $86K+4200.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SER Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | -4280.8% | N/A | N/A | -37942.9% |
| Net Margin | N/A | N/A | N/A | N/A | -4960.0% | N/A | N/A | 10071.4% |
| Return on Equity | -33.9%+323.9pp | -39.1%+243.8pp | N/A | -260.5% | -357.8% | -282.9% | N/A | N/A |
| Return on Assets | -24.6%+47.5pp | -25.3%+46.2pp | N/A | -36.9%-55.9pp | -72.1%-120.7pp | -71.5%+66.8pp | N/A | 19.0%+4.6pp |
| Current Ratio | 6.65+4.4x | 4.18+1.7x | 1.71-0.7x | 1.31+0.9x | 2.24+1.5x | 2.45+1.8x | 2.40-3.0x | 0.400.0x |
| Debt-to-Equity | 0.38-3.7x | 0.55-2.5x | N/A | 6.15 | 4.05 | 3.04 | 9.70 | N/A |
| Asset Turnover | 0.000.0x | N/A | N/A | 0.000.0x | 0.010.0x | 0.000.0x | N/A | 0.000.0x |
| FCF Margin | N/A | N/A | N/A | N/A | -2920.0% | N/A | N/A | -21178.6% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$37K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Serina Therapeutics SER | FY2025 | $130K | -$19.2M | N/A | $63.5M | — |
| Vtv Therapeutics VTVT | FY2025 | $0 | -$27.0M | N/A | $131.9M | — |
| Polypid Ltd. PYPD | FY2025 | N/A | -$34.2M | N/A | $109.5M | — |
| JUPITER NEUROSCIENCES, INC. JUNS | FY2025 | $22K | -$8.6M | N/A | $4.3M | — |
| Relmada Therapeutics Inc RLMD | FY2025 | N/A | $0 | N/A | $472.5M | — |
| MAIA Biotechnology Inc. MAIA | FY2025 | N/A | -$22.4M | N/A | $80.3M | — |
Where Serina Therapeutics Ranks
Frequently Asked Questions
What is Serina Therapeutics's annual revenue?
Serina Therapeutics (SER) reported $130K in total revenue for fiscal year 2025. This represents a 132.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Serina Therapeutics's revenue growing?
Serina Therapeutics (SER) revenue grew by 132.1% year-over-year, from $56K to $130K in fiscal year 2025.
Is Serina Therapeutics profitable?
No, Serina Therapeutics (SER) reported a net income of -$19.2M in fiscal year 2025.
What is Serina Therapeutics's EBITDA?
Serina Therapeutics (SER) had EBITDA of -$23.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Serina Therapeutics's free cash flow?
Serina Therapeutics (SER) recorded an outflow of $18.0M in free cash flow during fiscal year 2025. This represents a -5.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Serina Therapeutics's operating cash flow?
Serina Therapeutics (SER) recorded an outflow of $18.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Serina Therapeutics's total assets?
Serina Therapeutics (SER) had $7.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Serina Therapeutics's capital expenditures?
Serina Therapeutics (SER) invested $59K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Serina Therapeutics spend on research and development?
Serina Therapeutics (SER) invested $13.2M in research and development during fiscal year 2025.
What is Serina Therapeutics's current ratio?
Serina Therapeutics (SER) had a current ratio of 1.71 as of fiscal year 2025, which is generally considered healthy.
What is Serina Therapeutics's return on assets (ROA)?
Serina Therapeutics (SER) had a return on assets of -276.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Serina Therapeutics's P/E ratio?
Serina Therapeutics (SER) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $63.5M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Serina Therapeutics's price-to-sales ratio?
Serina Therapeutics (SER) trades at 488x sales, its market capitalization divided by revenue of $130K revenue, FY2025. The market capitalization is $63.5M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Serina Therapeutics's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Serina Therapeutics (SER) held $3.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $18.0M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Serina Therapeutics's debt-to-equity ratio negative or not reported?
Serina Therapeutics (SER) has negative shareholder equity of -$37K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Serina Therapeutics's Altman Z-Score?
Serina Therapeutics (SER) has an Altman Z-Score of -18.29, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Serina Therapeutics's Piotroski F-Score?
Serina Therapeutics (SER) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Serina Therapeutics's earnings high quality?
Serina Therapeutics (SER) reported a net loss of $19.2M while operations used $18.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Serina Therapeutics cover its interest payments?
Serina Therapeutics (SER) reported an operating loss of $24.0M against $213K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.